FDA bets on AI and cloud monitoring for clinical trials as it looks to rebuild after DOGE layoffs

The FDA launched a pilot to use AI and cloud tools for real-time clinical trial monitoring.

AstraZeneca and Amgen are the first partners, with the agency seeking more proposals for AI-driven trial improvements.

Instead of massive post hoc document uploads, the program will ingest direct data feeds from ongoing trials.

Officials say the effort could shorten trial timelines, cut paperwork, and help rebuild capacity after layoffs, though AI oversight remains a concern.